Saline ( DrugBank: - )


6 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病15
13多発性硬化症/視神経脊髄炎9
53シェーグレン症候群4
67多発性嚢胞腎3
168エーラス・ダンロス症候群1
299嚢胞性線維症53

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05435755
(ClinicalTrials.gov)
December 2, 202215/3/2022Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.The Precise Transplantation of Human Amniotic Epithelial Stem Cells Into the Ventricle Through Surgical Robot in the Treatment of Parkinson's Disease.Parkinson's DiseaseBiological: hAESCs treatment;Biological: placebo (saline)Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaNot yet recruiting30 Years70 YearsAll12Early Phase 1China
2NCT05197439
(ClinicalTrials.gov)
December 1, 20225/1/2022Dexmedetomidine Prevents Postoperative Delirium After Deep Brain Stimulation in Patients With Parkinson's DiseaseEffect of Dexmedetomidine on Postoperative Delirium in Elderly Patients With Parkinson's Disease Undergoing Deep Brain Stimulation: a Randomized Controlled TrialDexmedetomidine;Postoperative Delirium;Deep Brain StimulationDrug: Dexmedetomidine;Drug: 0.9% salineBeijing Tiantan HospitalNULLNot yet recruiting60 YearsN/AAll192N/AChina
3NCT04944017
(ClinicalTrials.gov)
November 23, 202122/6/2021Ketamine for the Treatment of Depression in Parkinson's DiseaseKetamine for the Treatment of Depression in Parkinson's Disease (KET-PD)Parkinson's Disease;DepressionDrug: Ketamine Infusion;Other: Placebo - Saline InfusionYale UniversityFox (Michael J.) Foundation for Parkinson's ResearchRecruiting40 Years80 YearsAll56Phase 2United States
4NCT04687878
(ClinicalTrials.gov)
January 1, 202028/12/2020The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease PatientsEvaluating the Effect of Intranasal Insulin Administration on Motor and Non-motor Symptoms in Parkinson's Disease Patients; a Randomized Double-blinded Placebo-controlled Clinical TrialParkinson DiseaseDrug: Insulin;Drug: Normal salinedr.dargahiNULLRecruiting17 YearsN/AAll40Phase 2Iran, Islamic Republic of
5NCT04202757
(ClinicalTrials.gov)
September 14, 201821/9/2018Intravenous Plasma Treatment for Parkinson's DiseaseIntravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease - Randomized Controlled StudyIdiopathic Parkinson DiseaseBiological: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors;Other: SalineThe Neurology CenterCarolina Longevity InstituteCompleted45 Years90 YearsAll18Phase 4United States
6ChiCTR2000037957
2016-12-012020-09-07Clinical study of dexmedetomidine on deep brain stimulation in middle-aged and elderly patients with Parkinson's diseaseClinical study of dexmedetomidine on deep brain stimulation in middle-aged and elderly patients with Parkinson's disease Deep brain stimulation in patients with Parkinson's diseaseExperimental group:conscious sedation with dexmedetomidine;control group:Pump in normal saline;Shanghai Jing'an District Central HospitalNULLCompleted4575BothExperimental group:27;control group:9;China
7NCT02018406
(ClinicalTrials.gov)
December 201330/10/2013Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain InjuryNeurological Diseases;Ischemic Stroke;Hemorrhagic Stroke;Cerebral Palsy;Atypical Parkinson DiseaseDrug: Combination injection of EPO and G-CSF;Drug: Injection of normal salineYonsei UniversityNULLActive, not recruiting20 YearsN/AAll16Phase 1/Phase 2Korea, Republic of
8JPRN-UMIN000017695
2013/01/0127/05/2015Oxybuprocaine for apraxia of lid opening in Parkinson's diseaseOxybuprocaine for apraxia of lid opening in Parkinson's disease - Oxybuprocain for ALO apraxia of lid opening in Parkinson's diseaseArm 1 intervention consisted of 4%oxybuprocaine eye drop treatment, washout for 24 hours or more, and a saline eye drop treatment
Arm 2 intervention consisted of saline eye drop treatment, a washout period, and an oxybuprocaine treatment
Utano National Hospital, National Hospital OrganizationNULLComplete: follow-up completeNot applicableNot applicableMale and Female10Not selectedJapan
9JPRN-UMIN000009099
2012/10/0112/10/2012The effect of lidocaine injection into the external oblique in Parkinson's disease patients with upper camptorcormiaThe effect of lidocaine injection into the external oblique in Parkinson's disease patients with upper camptorcormia - The effect of lidocaine injection in Parkinson's disease patients with camptorcormia Parkinson's diseaselidocaine injection into the external oblique
normal saline injection into the external oblique
Parkinson's disease and Movement Disorder CenterNULLRecruiting20years-oldNot applicableMale and Female10Not applicableJapan
10NCT02419313
(ClinicalTrials.gov)
August 201227/1/2014Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized ApproachInvestigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized ApproachParkinson;TremorDrug: incobotulinumtoxinA;Drug: SalineYale UniversityNULLCompleted18 YearsN/AAll33Phase 2United States
11NCT01398748
(ClinicalTrials.gov)
July 201219/7/2011Intranasal Glutathione in Parkinson's DiseaseA Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's DiseaseParkinson's Disease (PD)Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal DeliveryBastyr UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed21 Years100 YearsAll34Phase 1United States
12NCT01313819
(ClinicalTrials.gov)
April 201110/3/2011The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic TherapyA Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic TherapyParkinson`s Disease;Freezing of GaitDrug: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml injSeoul National University HospitalNULLRecruiting30 Years80 YearsBoth20Phase 4Korea, Republic of
13NCT01229332
(ClinicalTrials.gov)
January 20113/10/2010A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease PatientsA Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor FluctuationsParkinson's DiseaseDrug: Saline;Drug: CarbidopaNeuroDerm Ltd.NULLCompleted30 YearsN/ABoth24Phase 1/Phase 2Israel
14NCT00608231
(ClinicalTrials.gov)
January 20087/1/2008Dexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationDexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationParkinson's Disease;Essential Tremor;DystoniaDrug: Dexmedetomidine Hydrochloride Infusion;Drug: Normal SalineVanderbilt UniversityNULLWithdrawn18 YearsN/ABoth0Phase 2/Phase 3United States
15NCT00623363
(ClinicalTrials.gov)
April 20072/1/2008Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's DiseaseParkinson's DiseaseDrug: piclozotan;Drug: 0.9% sodium chloride (normal saline)Asubio Pharmaceuticals, Inc.NULLCompleted40 Years85 YearsBoth27Phase 2United States;Guatemala;Romania

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04979650
(ClinicalTrials.gov)
May 22, 20212/7/2021Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple SclerosisCorticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to a Non-enhancing Black Hole With or Without Treatment in MS Clinic of Booalisina Hospital Sari 2021-2023Multiple Sclerosis, Relapsing-Remitting;Magnetic Resonance Imaging;MethylprednisoloneDrug: Methylprednisolone succinate;Drug: Normal salineMazandaran University of Medical SciencesNULLEnrolling by invitation18 Years55 YearsAll104Phase 2Iran, Islamic Republic of
2NCT03355365
(ClinicalTrials.gov)
September 21, 201814/11/2017Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple SclerosisAutologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered IntrathecallyMultiple SclerosisBiological: Intrathecal MSC-NP injection;Other: Intrathecal saline injectionTisch Multiple Sclerosis Research Center of New YorkNULLActive, not recruiting18 Years65 YearsAll50Phase 2United States
3NCT02228213
(ClinicalTrials.gov)
October 201421/8/2014Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple SclerosisA Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisBiological: MIS416;Drug: SalineInnate ImmunotherapeuticsINC ResearchCompleted18 Years70 YearsAll93Phase 2Australia;New Zealand
4NCT01911377
(ClinicalTrials.gov)
October 201325/7/2013Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MSThe Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple SclerosisNeuropathic Pain;AllodyniaDrug: Botulinum Toxin Type A;Drug: Normal Saline for InjectionUniversity of ManitobaAllerganTerminated18 Years70 YearsBoth12Phase 2Canada
5NCT01600716
(ClinicalTrials.gov)
June 13, 201215/5/2012Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)Urinary Incontinence;Multiple Sclerosis;Neurogenic BladderBiological: OnabotulinumtoxinA;Drug: Placebo (Normal Saline)AllerganNULLCompleted18 YearsN/AAll144Phase 3United States;Belgium;Canada;Czechia;France;Poland;Portugal;Russian Federation;Czech Republic
6NCT01435993
(ClinicalTrials.gov)
September 8, 201125/8/2011Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple SclerosisA Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.Multiple Sclerosis, Relapsing-RemittingDrug: GSK1223249;Other: Saline placeboGlaxoSmithKlineNULLTerminated18 Years60 YearsAll3Phase 1Italy;Norway;Germany
7NCT01212094
(ClinicalTrials.gov)
September 201029/9/2010Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)Multiple SclerosisDrug: Rituximab;Other: normal salineNational Institute of Neurological Disorders and Stroke (NINDS)NULLTerminated18 Years65 YearsAll44Phase 1/Phase 2United States
8NCT00986960
(ClinicalTrials.gov)
December 200929/9/2009Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up StudyMultiple SclerosisDrug: repository corticotropin injection;Drug: SalineUniversity at BuffaloNULLTerminated18 Years65 YearsAll3Phase 2United States
9NCT01091727
(ClinicalTrials.gov)
October 200622/3/2010Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor OveractivityProspective Randomized Double-blind Trial of Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity and Urinary Incontinence Related to Spinal Cord Injury or Multiple SclerosisNeurogenic Detrusor OveractivityDrug: Botulinum toxin ASunnybrook Health Sciences Centreethica Clinical Research Inc.Completed18 Years75 YearsBoth57Phase 3Canada

53. シェーグレン症候群


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100052314
2021-11-012021-10-24Effect of triamcinolone acetonide for parotid gland lavage on the salivary secretion of patients with Sjogren's syndromeEffect of triamcinolone acetonide irrigation through parotid duct for parotid gland salivary secretion of patients with Sjogren's syndrome Sjogren syndromeExperimental Group:Perfusing parotid gland with triamcinolone acetonide injection through parotid duct;Control Group:The parotid gland was perfused with normal saline through parotid duct;Affiliated Stomatological Hospital of Nanjing Medical UniversityNULLPending2080BothExperimental Group:27;Control Group:27;Phase 4China
2NCT02112019
(ClinicalTrials.gov)
June 20148/4/2014Endoscopic Treatment of Salivary Glands Affected by Sjögren's SyndromeEndoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome; A Randomised Controlled Pilot StudySjögren's SyndromeProcedure: Sialoendoscopy;Drug: saline;Drug: hydrocortisoneDerk Jan JagerNULLActive, not recruiting18 Years70 YearsAll50N/ANetherlands
3NCT01357447
(ClinicalTrials.gov)
May 201118/5/2011Pulmozyme for Sjogren's Associated CoughA Double-blind, Placebo-controlled Cross-over Trial of Pulmozyme for Sjogren's Associated CoughSjogren's Syndrome;CoughDrug: Dornase alfa;Drug: SalineUConn HealthNULLWithdrawn18 YearsN/AAll0Phase 1United States
4EUCTR2007-001708-19-FR
(EUCTR)
23/08/200706/08/2007A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, phase III trial.A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, phase III trial. treatment on bilateral moderate dry eye syndrome due to Sjögren's syndrome or diagnosed as a primary syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10013774;Term: Dry eye
Product Name: SVS20
Product Code: SVS20
INN or Proposed INN: sodium hyaluronate
Trade Name: Lacryvisc
INN or Proposed INN: carbomer 974P
Product Name: SALINE
INN or Proposed INN: sodium chloride
TRB CHEMEDICA INTERNATIONAL SANULLNot RecruitingFemale: yes
Male: yes
300Phase 3France;United Kingdom

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02127437
(ClinicalTrials.gov)
September 19, 20142/4/2014Lanreotide In Polycystic Kidney Disease StudyLanreotide In Polycystic Kidney Disease StudyAutosomal Dominant Polycystic Kidney Disease (ADPKDDrug: Lanreotide;Drug: salineAssistance Publique - Hôpitaux de ParisIPSEN pharmaceutical company, Boulogne-Billancourt, FranceCompleted18 YearsN/AAll159Phase 3France
2NCT01377246
(ClinicalTrials.gov)
May 201120/6/2011Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyA PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCYAutosomal Dominant Polycystic Kidney DiseaseDrug: Octreotide-LAR;Other: Saline solution.Mario Negri Institute for Pharmacological ResearchNULLCompleted18 Years75 YearsAll100Phase 3Italy
3NCT00309283
(ClinicalTrials.gov)
April 200630/3/2006Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyEffect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up StudyAutosomal Dominant Polycystic Kidney Disease (ADPKD)Drug: Long-acting somatostatin;Other: Saline solutionMario Negri Institute for Pharmacological ResearchNULLCompleted18 Years75 YearsBoth78Phase 3Italy

168. エーラス・ダンロス症候群


臨床試験数 : 13 薬物数 : 21 - (DrugBank : 11) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01446783
(ClinicalTrials.gov)
September 201127/9/2011IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsIGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsEhlers-Danlos Syndrome, ClassicDrug: mecasermin;Drug: SalineBispebjerg HospitalNULLCompleted18 YearsN/ABoth15N/ADenmark

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004143-39-IT
(EUCTR)
19/12/201820/09/2018Saline hypertonic in preschoolers and lung structure as measured by computed tomography.A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Hypertonic saline
INN or Proposed INN: SODIUM CHLORIDE 7%
Other descriptive name: SODIUM CHLORIDE 7%
Product Name: Isotonic saline
INN or Proposed INN: SODIUM CHLORIDE SOLUTION 0.9%
Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%
Erasmus MCNULLNot RecruitingFemale: yes
Male: yes
120Phase 3France;United States;Spain;Belgium;Denmark;Australia;Netherlands;Italy
2NCT03375047
(ClinicalTrials.gov)
May 10, 20187/9/2017Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic FibrosisA Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 Administered by Nebulization to Adult Subjects With Cystic FibrosisCystic FibrosisDrug: MRT5005;Drug: Normal salineTranslate Bio, Inc.NULLRecruiting18 YearsN/AAll40Phase 1/Phase 2United States
3NCT03460704
(ClinicalTrials.gov)
January 29, 201814/2/2018Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS II)A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)Non Cystic Fibrosis BronchiectasisDrug: Colistimethate sodium;Drug: Saline SolutionZambon SpANULLCompleted18 Years90 YearsAll287Phase 3United States;Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal
4NCT03078088
(ClinicalTrials.gov)
June 15, 20171/3/2017Airway Alkalinization and Nasal ColonizationAirway Alkalinization and Nasal ColonizationHealthy Subjects;Cystic FibrosisDrug: Tham;Drug: SalineLakshmi DurairajNULLCompleted16 YearsN/AAll32Phase 1United States
5NCT03093974
(ClinicalTrials.gov)
June 6, 20179/3/2017Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection.A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)Non Cystic Fibrosis BronchiectasisDrug: Colistimethate Sodium;Drug: Saline SolutionZambon SpANULLCompleted18 YearsN/AAll377Phase 3Australia;Belgium;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom
6EUCTR2015-004143-39-ES
(EUCTR)
19/04/201731/03/2017Saline hypertonic in preschoolers and lung structure as measured by computed tomography.A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study Cystic Fibrosis
MedDRA version: 19.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 19.1;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Hypertonic saline
INN or Proposed INN: HYPERTONIC SALINE
Other descriptive name: SALINE
Product Name: Isotonic saline
INN or Proposed INN: ISOTONIC SALINE
Other descriptive name: STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V)
Erasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 3United States;Spain;Denmark;Australia;Netherlands
7EUCTR2015-004143-39-DK
(EUCTR)
14/02/201725/10/2016Saline Hypertonic in Preschoolers with cystic fibrosis and lung structure asmeasured by computedtomography (CT). SHIP-CT study.A Phase 3 randomised, double-blind, controlled trial of inhaled 7%hypertonic saline versus0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6years of age inparallel with the North American SHIP clinical trial - Ship-CT study Cystic fibrosis
MedDRA version: 19.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Hypertonic saline
INN or Proposed INN: sodium chloride 7%
Other descriptive name: SODIUM CHLORIDE 7%
Product Name: Isotonic saline 0.9%
INN or Proposed INN: SODIUM CHLORIDE SOLUTION 0.9%
Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%
Erasmus MCNULLNot RecruitingFemale: yes
Male: yes
120Phase 3France;United States;Spain;Belgium;Australia;Denmark;Netherlands;Italy
8EUCTR2015-004841-13-CZ
(EUCTR)
04/01/201710/08/2016A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationA Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: VX-371 in hypertonic saline
INN or Proposed INN: Not yet assigned
Other descriptive name: VX-371
Product Code: VX-371 in saline
INN or Proposed INN: Not yet assigned
Other descriptive name: VX-371
Trade Name: Orkambi
Product Name: lumacaftor/ivacaftor 200mg/125mg
Product Code: VX-809/VX-770
INN or Proposed INN: IVACAFTOR
Other descriptive name: Ivacaftor
INN or Proposed INN: Lumacaftor
Other descriptive name: LUMACAFTOR
Product Name: Hypertonic saline
INN or Proposed INN: 4.2% NaCl/inhalation solution
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
150Phase 2France;United States;Czech Republic;Ireland;United Kingdom
9NCT02947126
(ClinicalTrials.gov)
January 201725/10/2016Multilevel Models of Therapeutic Response in the LungsMultilevel Models of Therapeutic Response in the LungsCystic FibrosisDrug: Hypertonic Saline;Drug: Isotonic Saline;Drug: Indium-DTPA;Drug: Technetium Sulfur ColloidTim CorcoranNational Heart, Lung, and Blood Institute (NHLBI)Completed12 YearsN/AAll56Phase 1United States
10EUCTR2015-004143-39-BE
(EUCTR)
30/11/201613/10/2016Saline hypertonic in preschoolers and lung structure as measured by computed tomography.A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study Cystic Fibrosis
MedDRA version: 19.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 19.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Hypertonic saline
INN or Proposed INN: SODIUM CHLORIDE 7%
Other descriptive name: SODIUM CHLORIDE 7%
Product Name: Isotonic saline
INN or Proposed INN: SODIUM CHLORIDE SOLUTION 0.9%
Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%
Erasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 3United States;Spain;Belgium;Denmark;Australia;Netherlands
11NCT02657473
(ClinicalTrials.gov)
August 13, 201613/1/2016Inhaled Nebulized Tobramycin in Non-cystic Fibrosis BronchiectasisLong-term Inhaled Nebulized Tobramycin in Patients With Non-cystic Fibrosis Bronchiectasis. A Randomized Placebo Controlled Trial. The BATTLE Study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy.Non-CF BronchiectasisDrug: tobramycin inhalation solution;Drug: Saline 0.9% inhalation solutionMedical Center AlkmaarNULLCompleted18 YearsN/AAll58Phase 2/Phase 3Netherlands
12EUCTR2015-004143-39-NL
(EUCTR)
09/08/201621/12/2015Saline hypertonic in preschoolers and lung structure as measured by computed tomography.A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Hypertonic saline
INN or Proposed INN: SODIUM CHLORIDE 7%
Other descriptive name: SODIUM CHLORIDE 7%
Product Name: Isotonic saline
INN or Proposed INN: SODIUM CHLORIDE SOLUTION 0.9%
Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%
Erasmus MCNULLNot RecruitingFemale: yes
Male: yes
120Phase 3France;United States;Spain;Belgium;Denmark;Australia;Netherlands;Italy
13EUCTR2015-004841-13-IE
(EUCTR)
08/08/201607/06/2016A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationA Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: VX-371 in hypertonic saline
INN or Proposed INN: not yet assigned
Other descriptive name: VX-371
Product Code: VX-371 in saline
INN or Proposed INN: Not yet assigned
Other descriptive name: VX-371
Trade Name: Orkambi
Product Name: lumacaftor/ivacaftor 200mg/125mg
Product Code: VX-809/VX-770
INN or Proposed INN: IVACAFTOR
INN or Proposed INN: Lumacaftor
Other descriptive name: LUMACAFTOR
Product Name: Hypertonic Saline
INN or Proposed INN: 4.2% NaCl/Inhalation solution
Vertex Pharmaceuticals Inc.NULLNot RecruitingFemale: yes
Male: yes
150Phase 2France;United States;Czech Republic;Ireland;United Kingdom
14EUCTR2015-004841-13-GB
(EUCTR)
20/07/201609/06/2016A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationA Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: VX-371 in hypertonic saline
INN or Proposed INN: Not yet assigned
Other descriptive name: VX-371
Product Code: VX-371 in saline
INN or Proposed INN: Not yet assigned
Other descriptive name: VX-371
Trade Name: Orkambi
Product Name: lumacaftor/ivacaftor 200mg/125mg
Product Code: VX-809/VX-770
INN or Proposed INN: IVACAFTOR
INN or Proposed INN: Lumacaftor
Other descriptive name: LUMACAFTOR
Product Name: Hypertonic saline
INN or Proposed INN: 4.2% NaCl/Inhalation solution
Vertex Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes
150 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;United States;Czech Republic;Ireland;United Kingdom
15NCT02354859
(ClinicalTrials.gov)
March 201630/7/2014A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)Cystic FibrosisDrug: Gallium nitrate;Drug: Normal SalineUniversity of WashingtonCystic Fibrosis FoundationCompleted18 YearsN/AAll119Phase 2United States
16NCT02709109
(ClinicalTrials.gov)
February 201629/2/2016A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationA Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With OrkambiCystic FibrosisDrug: VX-371;Drug: Saline;Drug: Placebo;Drug: OrkambiParion SciencesVertex Pharmaceuticals IncorporatedCompleted12 YearsN/AAll142Phase 2United States;France;Ireland;United Kingdom
17NCT02343445
(ClinicalTrials.gov)
April 201513/1/2015Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients With Cystic Fibrosis (CF)Cystic FibrosisDrug: P-1037;Drug: Hypertonic Saline;Drug: SalineParion SciencesVertex Pharmaceuticals IncorporatedCompleted12 Years80 YearsAll142Phase 2United States
18NCT02950883
(ClinicalTrials.gov)
March 24, 201527/10/2016Saline Hypertonic in Preschoolers + CTSaline Hypertonic in Preschoolers With Cystic Fibrosis and Lung Structure as Measured by Computed Tomography (CT)Cystic FibrosisDrug: Active Treatment Group 7% Hypertonic Saline;Drug: Control Group 0.9% Isotonic SalineUniversity of Washington, the Collaborative Health Studies Coordinating CenterCystic Fibrosis FoundationCompleted3 Years5 YearsAll116Phase 2/Phase 3United States;Australia;Belgium;Canada;Denmark;France;Italy;Netherlands;Spain
19NCT02378467
(ClinicalTrials.gov)
March 1, 201527/2/2015Saline Hypertonic in PreschoolersSaline Hypertonic in PreschoolersCystic FibrosisDrug: 7% Hypertonic Saline (HS);Drug: 0.9% Isotonic Saline (IS)University of Washington, the Collaborative Health Studies Coordinating CenterCystic Fibrosis FoundationCompleted3 Years5 YearsAll150N/AUnited States;Canada
20NCT02141191
(ClinicalTrials.gov)
June 201412/5/2014A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD DeviceA Randomized Crossover Mucociliary Clearance Study of Aerosolized 7% NaCl Solution Administered Overnight by the tPAD Device to Subjects With Cystic FibrosisCystic FibrosisDrug: inhaled hypertonic saline (7%)University of PittsburghParion SciencesCompleted18 YearsN/AAll12Phase 1United States
21NCT02081963
(ClinicalTrials.gov)
March 20146/3/2014Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis BronchiectasisA Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis BronchiectasisNon-Cystic Fibrosis BronchiectasisDrug: Amikacin;Drug: Normal salineQilu Hospital of Shandong UniversityNULLCompleted18 Years80 YearsAll178Phase 4China
22NCT01746784
(ClinicalTrials.gov)
February 20146/12/2012Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR MutationA Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO1)Cystic FibrosisDrug: N6022;Drug: Normal salineNivalis Therapeutics, Inc.NULLCompleted18 YearsN/AAll66Phase 1United States
23NCT01887197
(ClinicalTrials.gov)
June 201324/6/2013Repeatability and Response Study of Absorptive Clearance ScansRepeatability and Response Study of Absorptive Clearance ScansCystic FibrosisOther: Absorptive clearance scan;Drug: inhaled hypertonic saline (7%);Drug: mannitol inhalation powderTim CorcoranNULLCompleted18 YearsN/AAll24Phase 1United States
24NCT00928135
(ClinicalTrials.gov)
January 22, 201318/6/2009Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) SubjectsRandomized Controlled Study of Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Hospitalized Patients With Exacerbation of Cystic FibrosisCystic FibrosisDrug: Xylitol;Drug: SalineJoseph ZabnerNULLCompleted12 YearsN/AAll63Phase 1/Phase 2United States
25NCT01619657
(ClinicalTrials.gov)
June 201212/6/2012Preventive Inhalation of Hypertonic Saline in Infants With Cystic FibrosisRandomized, Double-blind, Controlled Pilot Study on Safety of Hypertonic Saline as Preventive Inhalation Therapy in Newborns and Infants With Cystic FibrosisCystic Fibrosis Lung DiseaseDrug: 6% Hypertonic Saline (HS), 4mL;Drug: 0.9% Isotonic Saline (IS), 4mLHeidelberg UniversityGerman Center for Lung ResearchCompletedN/A4 MonthsAll42Phase 2Germany
26NCT02276898
(ClinicalTrials.gov)
November 201122/10/2014A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance IndexA Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index as a Short-term Pharmacodynamic Biomarker in Patients With Cystic Fibrosis.Cystic FibrosisDrug: Hypertonic Saline 7%;Drug: Isotonic Saline 0.9% (Placebo)The Hospital for Sick ChildrenNULLCompleted6 Years18 YearsBoth24Phase 2Canada
27NCT01465529
(ClinicalTrials.gov)
May 201131/10/2011A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. FibrosisA Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis Chronically Colonised With Pseudomonas AeruginosaCystic FibrosisDrug: OligoG CF-5/20;Drug: SalineAlgiPharma ASNULLCompleted18 YearsN/ABoth26Phase 1/Phase 2Ireland;United Kingdom
28NCT01355796
(ClinicalTrials.gov)
May 201116/5/2011Inhaled Xylitol Versus Saline in Stable Subjects With Cystic FibrosisRandomized Cross Over Study of Inhaled Hypertonic Xylitol Versus Hypertonic Saline in Stable Subjects With Cystic FibrosisCystic FibrosisDrug: Xylitol;Drug: Hypertonic salineJoseph ZabnerAnn & Robert H Lurie Children's Hospital of Chicago;Northwestern UniversityCompleted16 YearsN/AAll30Phase 1/Phase 2United States
29NCT01223183
(ClinicalTrials.gov)
September 201014/10/2010Absorptive Clearance After Inhaled Osmotics in Cystic FibrosisAbsorptive Clearance After Inhaled Osmotics in Cystic FibrosisCystic FibrosisDrug: hypertonic saline (7%);Drug: isotonic salineUniversity of PittsburghNULLCompleted18 YearsN/AAll20Phase 1United States
30NCT00996424
(ClinicalTrials.gov)
January 201015/10/2009The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung FunctionThe Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function.Cystic FibrosisDrug: Acetylcysteine;Drug: normal salineUniversity Hospital, GhentBVSMTerminated6 Years64 YearsBoth19Phase 4Belgium
31EUCTR2008-008317-20-BE
(EUCTR)
13/11/200921/09/2009The effect of inhaled N-Acetylcysteine compared to normal saline on sputum rheology and lung functionThe effect of inhaled N-Acetylcysteine compared to normal saline on sputum rheology and lung function Cystic Fibrosis
MedDRA version: 12.0;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Trade Name: Lysomucil 10 %
Product Name: N-acetylcysteine
INN or Proposed INN: Acetylcysteine
University Hospital GhentNULLNot RecruitingFemale: yes
Male: yes
Belgium
32NCT01094704
(ClinicalTrials.gov)
November 200919/3/2010Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic FibrosisDurability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic FibrosisCystic FibrosisDrug: sodium chloride (7%)University of North Carolina, Chapel HillJohns Hopkins University;Novartis PharmaceuticalsCompleted18 YearsN/AAll16Phase 1United States
33NCT01031706
(ClinicalTrials.gov)
September 200911/12/2009Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic FibrosisSustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic FibrosisCystic FibrosisDrug: Hypertonic Saline;Drug: PlaceboUniversity of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)Completed5 Years12 YearsAll23N/AUnited States
34NCT01880723
(ClinicalTrials.gov)
May 200915/6/2013Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic FibrosisModifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ ChannelsCystic Fibrosis;HealthyDrug: Albuterol;Drug: Placebo salineUniversity of ArizonaNational Heart, Lung, and Blood Institute (NHLBI)Completed15 Years55 YearsAll32N/AUnited States
35NCT00709280
(ClinicalTrials.gov)
April 20091/7/2008Infant Study of Inhaled Saline in Cystic FibrosisInfant Study of Inhaled Saline in Cystic FibrosisCystic FibrosisDrug: 7% Hypertonic Saline (HS);Drug: 0.9% Isotonic Saline (IS)CF Therapeutics Development Network Coordinating CenterCystic Fibrosis Foundation Therapeutics;National Heart, Lung, and Blood Institute (NHLBI)Completed4 Months59 MonthsBoth321N/AUnited States;Canada
36NCT01377792
(ClinicalTrials.gov)
March 20099/5/2011Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic FibrosisPhase 4 Study of the Efficacy of Long-term Treatment With Hypertonic Saline on Pulmonary Exacerbations in Patients With Cystic FibrosisCystic FibrosisDrug: Hypertonic salineAdelaida Lamas FerreiroNULLCompleted6 YearsN/ABoth71Phase 4Spain
37NCT00700050
(ClinicalTrials.gov)
April 200816/6/2008Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis AirwaysModulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways - A Pilot StudyCystic FibrosisDrug: Hypertonic salineThe Hospital for Sick ChildrenUnity Health TorontoActive, not recruiting14 Years28 YearsAll80Canada
38NCT00635141
(ClinicalTrials.gov)
March 20084/3/2008The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic FibrosisThe Effect of Inhaled Hypertonic Saline (7%) Versus Normal Saline (0.9%) on the Lung Clearance Index in Patients With Cystic FibrosisCystic FibrosisDrug: hypertonic saline (7 %) and isotonic saline (0.9%)The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationCompleted6 Years18 YearsBoth20Phase 3Canada
39NCT00628134
(ClinicalTrials.gov)
March 200822/2/2008Self-dispersing Liquids as Aerosol Drug CarriersSelf-dispersing Liquids as Aerosol Drug CarriersCystic FibrosisDrug: calfactant;Drug: isotonic salineUniversity of PittsburghCystic Fibrosis Foundation TherapeuticsCompleted18 YearsN/AAll8N/AUnited States
40NCT00484263
(ClinicalTrials.gov)
December 20077/6/2007The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis BronchiectasisThe Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non-cystic Fibrosis Bronchiectasis.BronchiectasisDrug: Hypertonic saline 6% -The AlfredNULLCompleted18 YearsN/ABoth40Phase 3Australia
41NCT00534079
(ClinicalTrials.gov)
September 200721/9/2007Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic RhinosinusitisNasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis - a Double Blind Placebo-controlled Cross-over, Bicenter, Prospective Clinical StudyCystic Fibrosis;RhinosinusitisDrug: Dornase alfa (Pulmozyme);Drug: isotonic salineUniversity of JenaNULLCompleted5 YearsN/ABoth23Phase 3Germany
42NCT00546663
(ClinicalTrials.gov)
September 200717/10/2007Tolerability of Inhaled Hypertonic Saline in Infants With Cystic FibrosisA Pilot Study to Evaluate the Tolerability of Inhaled 7% Hypertonic Saline in Infants With Cystic FibrosisCystic FibrosisDrug: inhaled 7% hypertonic saline (HS)CF Therapeutics Development Network Coordinating CenterCystic Fibrosis Foundation TherapeuticsCompleted12 Months30 MonthsBoth19N/AUnited States;Canada
43NCT01293084
(ClinicalTrials.gov)
July 20079/2/2011Hypertonic Saline and Mucociliary Clearance in ChildrenAcute Inhalation of Hypertonic Saline Does Not Improve Mucociliary Clearance in All Children With Cystic FibrosisCystic FibrosisDrug: 0.12% saline;Drug: 7% salineJohns Hopkins UniversityCystic Fibrosis Foundation TherapeuticsCompleted7 Years12 YearsAll17Phase 2NULL
44NCT00506688
(ClinicalTrials.gov)
July 200724/7/2007Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis PatientsRandomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis PatientsCystic FibrosisDrug: reduced glutathione sodium salt;Drug: 0.9% normal saline (control)Mukoviszidose Institut gGmbHCystic Fibrosis Foundation TherapeuticsCompleted8 YearsN/ABoth153Phase 2Germany
45EUCTR2007-002707-40-BE
(EUCTR)
28/06/200704/06/2007The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in Cystic Fibrosis patients The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in Cystic Fibrosis patients Mucoviscidose
MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Hypertonic saline solution
INN or Proposed INN: Sodium Chloride
Product Name: Normal saline solution
INN or Proposed INN: Sodium Chloride
University Hospital GhentNULLNot RecruitingFemale: yes
Male: yes
60Belgium
46NCT00721071
(ClinicalTrials.gov)
December 200621/7/2008Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic FibrosisDiagnostic Utility of Induced Sputum Using Hypertonic Saline to Evaluate Airway Infection and Inflammation in Cystic FibrosisCystic FibrosisDrug: Hypertonic SalineThe Hospital for Sick ChildrenNULLCompleted6 Years18 YearsBoth95Phase 2Canada
47NCT00671723
(ClinicalTrials.gov)
October 200630/4/2008Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis PatientsDornase Alpha Versus Hypertonic Saline for Lung AtelectasisAtelectasisDrug: Normal saline:;Drug: Hypertonic Saline;Drug: Dornase alphaUniversity of OklahomaNULLCompleted18 Years90 YearsAll33N/AUnited States
48NCT00753987
(ClinicalTrials.gov)
March 200615/9/2008Tolerability of Hypertonic Saline in Infants With Cystic FibrosisTolerability of Hypertonic Saline in Infants With Cystic FibrosisCystic FibrosisDrug: Hypertonic SalineThe Hospital for Sick ChildrenNULLCompleted2 Months2 YearsBoth13Phase 1Canada
49NCT00163852
(ClinicalTrials.gov)
February 200412/9/2005Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic FibrosisSalt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic FibrosisCystic FibrosisDrug: Normal saline IV, salt tabletsBayside HealthNational Health and Medical Research Council, Australia;Monash University;Cystic Fibrosis AustraliaRecruiting18 Years75 YearsBoth40Phase 2/Phase 3Australia
50NCT00274391
(ClinicalTrials.gov)
July 20019/1/2006Efficacy of Amiloride and Hypertonic Saline in Cystic FibrosisEfficacy of Amiloride and Hypertonic Saline in Cystic FibrosisCystic FibrosisDrug: 7% NaCl;Drug: Amiloride HClUniversity of North CarolinaCystic Fibrosis Foundation TherapeuticsCompleted14 YearsN/ABoth24Phase 2United States
51NCT00271310
(ClinicalTrials.gov)
September 200029/12/2005The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic FibrosisThe Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic FibrosisCystic FibrosisDrug: hypertonic salineRoyal Prince Alfred Hospital, Sydney, AustraliaCystic Fibrosis Foundation Therapeutics;National Health and Medical Research Council, Australia;Cystic Fibrosis TrustCompleted6 YearsN/ABoth164Phase 3NULL
52EUCTR2015-004143-39-FR
(EUCTR)
30/03/2017Saline hypertonic in preschoolers and lung structure as measured by computed tomography.A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Hypertonic saline 7%
INN or Proposed INN: SODIUM CHLORIDE
Other descriptive name: SODIUM CHLORIDE PH. EUR.
Product Name: Isotonic saline 0.9%
INN or Proposed INN: SODIUM CHLORIDE
Other descriptive name: SODIUM CHLORIDE PH. EUR.
Erasmus MCNULLNot RecruitingFemale: yes
Male: yes
120Phase 3United States;France;Spain;Belgium;Denmark;Australia;Netherlands;Italy
53EUCTR2015-004841-13-FR
(EUCTR)
23/06/2016A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationA Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi Cystic Fibrosis
MedDRA version: 19.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: VX-371 in hypertonic saline
INN or Proposed INN: Not yet assigned
Other descriptive name: VX-371
Product Code: VX-371 in saline
INN or Proposed INN: Not yet assigned
Other descriptive name: VX-371
Trade Name: Orkambi
Product Name: lumacaftor/ivacaftor 200mg/125mg tablets
Product Code: VX-809/VX-770
INN or Proposed INN: IVACAFTOR
Other descriptive name: Ivacaftor
INN or Proposed INN: Lumacaftor
Other descriptive name: LUMACAFTOR
Product Name: Hypertonic saline
INN or Proposed INN: 4.2% NaCl/inhalation solution
Vertex Pharmaceuticals Inc.NULLNot Recruiting Female: yes
Male: yes
150 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;France;Czech Republic;Ireland;United Kingdom